Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Scholar Rock Holding Corp (SRRK)
NASDAQ:SRRK
Holding SRRK?
Track your performance easily
SRRK Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.94 - $21.17
Previous Close$8.1
Volume572.16K
Average Volume (3M)793.30K
Market Cap
$648.26M
Enterprise Value$525.81M
Total Cash (Recent Filing)$190.49M
Total Debt (Recent Filing)$68.04M
Price to Earnings (P/E)―
Beta1.61
Next Earnings
Nov 11, 2024EPS Estimate
-$0.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.33
Shares Outstanding80,032,623
10 Day Avg. Volume634,084
30 Day Avg. Volume793,298
Standard Deviation0.29
R-Squared0.02
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)4.93
Price to Sales (P/S)498.66
Price to Cash Flow (P/CF)-3.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.05K
Enterprise Value/Gross Profit262.91
Enterprise Value/Ebitda-2.63
Forecast
1Y Price Target
$30.67Price Target Upside272.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Scholar Rock Holding News
PremiumCompany Announcements
Scholar Rock’s Advances in Obesity Management Drugs
PremiumCompany Announcements
Scholar Rock Unveils Promising Cancer Trial Results at ASCO 2024Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
SRRK FAQ
What was Scholar Rock Holding Corp’s price range in the past 12 months?
Scholar Rock Holding Corp lowest stock price was $5.94 and its highest was $21.17 in the past 12 months.
What is Scholar Rock Holding Corp’s market cap?
Currently, no data Available
When is Scholar Rock Holding Corp’s upcoming earnings report date?
Scholar Rock Holding Corp’s upcoming earnings report date is Nov 11, 2024 which is in 53 days.
How were Scholar Rock Holding Corp’s earnings last quarter?
Scholar Rock Holding Corp released its earnings results on Aug 08, 2024. The company reported -$0.6 earnings per share for the quarter, missing the consensus estimate of -$0.59 by -$0.01.
Is Scholar Rock Holding Corp overvalued?
According to Wall Street analysts Scholar Rock Holding Corp’s price is currently Undervalued.
Does Scholar Rock Holding Corp pay dividends?
Scholar Rock Holding Corp does not currently pay dividends.
What is Scholar Rock Holding Corp’s EPS estimate?
Scholar Rock Holding Corp’s EPS estimate is -$0.58.
How many shares outstanding does Scholar Rock Holding Corp have?
Scholar Rock Holding Corp has 80,032,620 shares outstanding.
What happened to Scholar Rock Holding Corp’s price movement after its last earnings report?
Scholar Rock Holding Corp reported an EPS of -$0.6 in its last earnings report, missing expectations of -$0.59. Following the earnings report the stock price went down -0.97%.
Which hedge fund is a major shareholder of Scholar Rock Holding Corp?
Among the largest hedge funds holding Scholar Rock Holding Corp’s share is Woodline Partners LP. It holds Scholar Rock Holding Corp’s shares valued at 6M.
---
Scholar Rock Holding Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.67 (272.21% Upside)
$30.67 (272.21% Upside)
Blogger Sentiment
Bullish
SRRK Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 359.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.7%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
26.56%
12-Months-Change
Fundamentals
Return on Equity
-121.29%
Trailing 12-Months
Asset Growth
-20.37%
Trailing 12-Months
Company Description
Scholar Rock Holding Corp
Scholar Rock Holding Corp. is a biopharmaceutical company, which engages in the development and discovery of innovative medicines. The company offers proprietary platform which designed to discover and develop monoclonal antibodies that have a high degree of specificity to achieve selective modulation of growth factor signaling. Its product candidate includes SRK-015 and SRK-181. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.
---
SRRK Earnings Call
Q2 2024
0:00 / 0:00
---
SRRK Stock 12 Month Forecast
Average Price Target
$30.67
▲(272.21% Upside)
Technical Analysis
Mirum Pharmaceuticals
―
Prelude Therapeutics
―
Fate Therapeutics
―
Blueprint Medicines
―
Best Analysts Covering SRRK
1 Year
1 Year Success Rate
7/14 ratings generated profit
1 Year Average Return
+2.89%
reiterated a buy rating last month
Copying Andres Y. Maldonado's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +2.89% per trade.
---